+1-888-308-5802     
News Contact Us

AB Inbev kicks off its second attempt of Asia IPO aiming $6.6 billion

Author : Saipriya Iyer | Published Date : 2019-09-18 

IPO activities witnessed a slowdown in the first quarter of 2019 owing to several geopolitical tensions like the trade war between China and United States or the intensifying EU, UK Brexit negotiations. Now, however, well-prepared enterprises are either looking for the right window of opportunity to go public or are kicking off their IPOs regardless.    

Anheuser-Busch InBev SA/NV, the multinational drink & brewing organization, reportedly announced the launch of its second attempt at an IPO in Hong Kong, targeting up to $6.6 billion. This might possibly be the second largest flotation of 2019 in the world.

The Belgian giant, that earlier in July tried to raise over $9.8 billion by an initial public offering (IPO) of the Budweiser Brewing Company APAC Ltd, recently stated that over 1.3 billion shares will be offered by it at between $3.45-$3.83 apiece.

The novel offering includes a unique "upsize" option which will enable the organization to trade up to 36.8% more shares. Assuming that the company uses this option completely at the topmost end of the offered price range, the sale could bring in up to $6.6 billion before any normal overallotment alternative is included.

If Budweiser APAC’s IPO is completed, it would further provide a boost for Hong Kong after China-based Alibaba Group Holding Ltd delayed a listing last month that would have been worth over $15 billion owing to the political tensions in the city.

Reports cite, so far in 2019, organizations have managed to raise $10.8 billion through IPOs in Hong Kong, China – quite less than the $41 billion gathered in New York.

The money raised from IPO would help the Belgian giant reduce a debt burden of more than $100 billion, accumulated after the acquisition of SABMiller earlier in 2016.

CEO of Budweiser APAC, Jan Craps stated that the current conditions are highly challenging, but after listening to potential investors the company believes that there is a strong anticipation about the business as well as its IPO.

The beer maker also plans to develop an Asian champion to spur alliances. The brewing assets of privately operating ThaiBev or Philippines’ San Miguel are expected to be the possible partners or targets of the company.

 

Source credit: https://economictimes.indiatimes.com/markets/ipos/fpos/ab-inbev-launches-second-asia-ipo-attempt-targets-up-to-6-6-billion/articleshow/71166973.cms

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

All Nippon Airways and Singapore Airlines to form new joint venture

Published Date: 2020-01-23         Author: Saipriya Iyer

Singapore Airlines, the flag carrier airline of Singapore, and All Nippon Airways, Japan’s largest airline in terms of passengers and revenue, are likely to form a new joint venture this month. The proposal, if approved by relevant authorities from both parties, would pave the way for ANA a... Read More

Broco Tactical to unveil 3 new products at 2020 SHOT Show in Las Vegas

Published Date: 2020-01-21         Author: Saipriya Iyer

Broco Tactical is reportedly introducing the latest line of forced entry and rescue & repair products in Las Vegas, Nevada, for military, law enforcement, and first responders at 2020 SHOT Show, from 21st-24th January. The California-based company is a part of the Broco Rankin family of companie... Read More

Zymeworks partners with Ibrance and initiates Phase 2 trial

Published Date: 2020-01-14         Author: Saipriya Iyer

Zymeworks Inc., a Vancouver based clinical stage biopharmaceutical company that develops multifunctional therapeutics, has reportedly announced the commencement of Phase 2 trial that assesses ZW25 combination therapy. The company also announced that it has reached consensus on an agreement with Pfiz... Read More

© 2020 Fractovia. All Rights Reserved